For healthcare professionals. This information does not replace clinical judgement in the individual case; the current summary of product characteristics and the guidelines cited are authoritative.
Medically reviewed: Dr. med. univ. Daniel Pehböck, DESA, 01.11.2026
Ipratropium bromide (Short-acting anticholinergic (SAMA)) – indications: Severe/life-threatening asthma attack – adults, Severe asthma attack – children ≤ 5 y, COPD exacerbation – adults. Weight-based dosing in mg and ml in the app, with sources.
Indications
- Severe/life-threatening asthma attack – adults
- Severe asthma attack – children ≤ 5 y
- COPD exacerbation – adults
Complete in the app
Weight-based doses in mg and ml, preparations, contraindications and notes – in the app, also offline.
Used in
Sources and guidelines
- Bundesärztekammer, KBV, AWMF. Nationale VersorgungsLeitlinie Asthma.
- Hossny E et al. Management of Asthma in Children 5 Years and Under. World Allergy Organization, Update 2020 (Zusammenfassung nach GINA).
- Summaries of product characteristics of authorised products – product and section for each dose in the app.